Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Incontinence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Erectile Dysfunction 1Carcinoma 1Adenocarcinoma 1

Interventions

Gemcitabine 57130-nm albumin-bound paclitaxel 35Specimen Handling 26Magnetic Resonance Spectroscopy 21Albumin-Bound Paclitaxel 21Fluorouracil 20Leucovorin 19Irinotecan 19Oxaliplatin 17Biopsy 17Taxes 16pembrolizumab 13Cyclophosphamide 11Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8Nivolumab 7Carboplatin 7irinotecan sucrosofate 6durvalumab 6dehydroftorafur 6Radiosurgery 6Pemetrexed 6olaparib 5Ipilimumab 5Erlotinib Hydrochloride 5trastuzumab deruxtecan 4aldesleukin 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Tadalafil × 90 days × Clear all
NCT05014776 2026-04-28

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
17 enrolled 8 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡